CBL-B - An upcoming immune-oncology target.

Introduction: The E3 ubiquitin ligase Cbl-b is a novel target in immune-oncology, with critical roles in regulating T-cell activation and signaling pathways. By facilitating the ubiquitination and degradation of key signaling proteins, Cbl-b modulates immune responses, maintaining immune homeostasis and preventing unwarranted T-cell proliferation. The therapeutic potential of Cbl-b as a cancer immunotherapy target is underscored by its contribution to an immunosuppressive tumor microenvironment, with efforts currently underway to develop small-molecule inhibitors.

A Label-Free Sensor Array Based on Carbon Quantum Dots for Detection of α-Synuclein Oligomers in Saliva.

Salivary oligomeric α-synuclein (α-Syn) has been introduced as a promising biomarker for the diagnosis of Parkinson's disease. Herein, a fluorescence sensor array based on three carbon quantum dots (CQDs) with different surface functional groups was developed for the identification and quantification of salivary α-Syn oligomers. Each of the CQDs generated a different fluorescence response to the target analyte, and the responses were analyzed by NPLS-DA to create a unique response pattern for the target analyte.

A FRET-based aptasensor for the detection of α-synuclein oligomers as biomarkers of Parkinson's disease.

Soluble oligomers of α-synuclein (α-syn) are known to be responsible for neuronal death in the early stages of Parkinson's disease (PD). Thus, the development of a simple, rapid, and inexpensive method for the detection of α-syn oligomers can help PD diagnosis before irreversible damage to the brain tissue occurs. The present study is aimed at developing a FRET-based aptasensor for the selective and sensitive detection of α-syn oligomers.